Register to receive a free Orthopedic Large Joint Replacement Devices Market Report Suite for US 2016 – 2022 report synopsis and brochure
OMNIlife science, Inc. recently announced that they have begun clinical evaluations of their exclusive OMNIBotics Active Spacer robotic tissue balancing device at three U.S. sites. This technology received 510(k) clearance from the FDA on September 1, 2017.
The OMNIBotics Active Spacer, in clinical use since March in Australia, provides the surgeon with a quantitative tool to actively manage the soft tissue envelope with dynamic real-time feedback. When combined with the accuracy of alignment and bone cuts provided by the OMNIBotics system, the result is a completely customized procedure from both a skeletal and a soft tissue perspective.
“I believe that the active spacer technology is the tool we have been looking for to create even better predictability and reproducibility for knee replacement surgery,” said Jeffrey M. Lawrence, M.D. Viroqua, WI. “I’m very excited to offer this system to my patients.”
Of his early experience, John M. Keggi, MD, Middlebury, CT said, “The active spacer technology is a great step forward that brings the most advanced measurement and analysis tools directly to each patient and surgeon right in the operating room. It’s an unprecedented, real-time evaluation of the knee that optimizes each step of the procedure.”
Studies indicate that a significant percentage of knee replacement patients do not achieve full satisfaction even with well-placed implants. One potential contributing factor is sub-optimal soft tissue balancing.
“The active spacer is an amazing new technology for knee replacement. It actually shows your surgeon, in real time, how tight or loose your knee is on each side as it bends. This information is then fed into a robot, which plans how your knee is replaced on an individual basis for optimum results,” said Amber Randall, MD an orthopedic surgeon in Arizona.
OMNI, a pioneer in robotic-assisted total knee replacement, now offers the only robotic technology that quantitatively drives the total knee replacement surgical procedure with both alignment and ligament balancing. Dr. Randall continues, “I believe that this revolutionary, never before seen technology will get us not one–but several–steps closer to the Holy Grail of knee replacement: the freely moving, perfectly stable and pain free knee.”
For Further Information
More on the orthopedic large joint market in the U.S. can be found in a series of reports published by iData Research entitled the US Market for Orthopedic Large Joint Replacement Devices. The suite covers reports on the following markets: Knee Replacement Devices, Hip Replacement Devices and Bone Cements.
The iData report series on orthopedic large joint devices covers the U.S., China, India, Japan, Australia, South Korea, Brazil and 15 countries in Europe including Austria, Belgium, Denmark, Finland, France, Germany, Italy, Luxembourg, Netherlands, Norway, Portugal, Spain, Sweden, Switzerland, and the United Kingdom. Reports provide a comprehensive analysis including units sold, procedure numbers, market value, forecasts, as well as detailed competitive market shares and analysis of major players’ success strategies in each market and segment. To find out more about orthopedic large joint devices market data or procedure data, register online or email us at email@example.com for a US Market for Orthopedic Large Joint Replacement Devices brochure and synopsis.